#USA #Marlborough #Boston Scientific #EKOS System #HI-PEITHO Trial

Introduction

The recent HI-PEITHO trial has unveiled groundbreaking results regarding the treatment of acute pulmonary embolism (PE) using the EKOS™ Endovascular System. Conducted by Boston Scientific Corporation, the trial has suggested that this innovative device, paired with anticoagulation therapy, outperforms the traditional standard of care, which solely relies on anticoagulants.

The Significance of Pulmonary Embolism

Pulmonary embolism is a potentially life-threatening condition wherein a blood clot clogs one or more pulmonary arteries. It stands as the third leading cause of cardiovascular-related deaths, highlighting the necessity for effective treatment options. Current medical guidelines advocate for anticoagulation as the primary treatment for all risk levels of PE, stressing the urgent need for improvements in management strategies.

Overview of the HI-PEITHO Trial

Unveiled at the American College of Cardiology's Annual Scientific Session 2026, the HI-PEITHO trial is a global, randomized clinical study involving 544 patients at 59 sites across the United States and Europe. Notably, the research was a collaborative effort alongside The PERT Consortium® and the University Medical Center of Mainz.

The trial aimed to assess the effectiveness of the EKOS device, which administers a low-dose clot-dissolving medication directly at the site of the clot while utilizing ultrasound energy to enhance drug dispersion within the clot. This technique not only promises quicker resolution of embolisms but also a lower risk of bleeding complications compared to traditional therapies.

Trial Outcomes

The findings from the HI-PEITHO trial were striking: patients treated with the EKOS system exhibited a remarkable 61% reduction in primary endpoint events concerning PE-related complications when compared to anticoagulation alone, achieving rates of 4.0% versus 10.3% respectively (P=0.005). Furthermore, patients in the EKOS group demonstrated a significantly reduced risk of cardiorespiratory decompensation—3.7% versus 10.3% in the traditional anticoagulation cohort.

The trial's positive results showcase the EKOS system's potential to decrease hospitalization times and offer treatment without elevating major bleeding risks, an essential concern in PE management. As highlighted by Dr. Stavros Konstantinides, the principal investigator, these findings reinforce the clinical utility of ultrasound-facilitated catheter-directed thrombolysis, providing clinicians with a robust alternative treatment.

Implications for Clinical Practice

The outcomes from the HI-PEITHO trial are particularly significant, offering definitive evidence that the EKOS system could emerge as a frontline therapy for acute pulmonary embolism. Dr. Michael R. Jaff, a leading figure at Boston Scientific, emphasized the importance of these results in guiding treatment decisions for interventionalists and referring healthcare providers. The data not only underscores the efficacy of the EKOS system but also highlights a pivotal moment in PE treatment protocols.

Conclusion

With the substantial evidence presented in the HI-PEITHO trial, the EKOS™ Endovascular System could redefine therapeutic approaches to acute pulmonary embolism, providing clinicians with enhanced options to address this critical condition effectively. Given the severe implications of untreated PE and the limitations of existing therapies, the future of treatment now looks promising with innovations like the EKOS system leading the way.

To learn more about the HI-PEITHO trial and its implications for pulmonary embolism treatment, visit Boston Scientific's official page.